Terms: = Germ cell tumor AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Prognosis
88 results:
1. Mesenchymal-Stem-cell-Based Therapy against Gliomas.
Santillán-Guaján SM; Shahi MH; Castresana JS
Cells; 2024 Apr; 13(7):. PubMed ID: 38607056
[TBL] [Abstract] [Full Text] [Related]
2. Identification of genetic modifiers enhancing B7-H3-targeting car T cell therapy against glioblastoma through large-scale CRISPRi screening.
Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
[TBL] [Abstract] [Full Text] [Related]
3. Targeting Wnt signaling for improved glioma immunotherapy.
Gutova M; Hibbard JC; Ma E; Natri HM; Adhikarla V; Chimge NO; Qiu R; Nguyen C; Melendez E; Aguilar B; Starr R; Yin H; Rockne RC; Ono M; Banovich NE; Yuan YC; Brown CE; Kahn M
Front Immunol; 2024; 15():1342625. PubMed ID: 38449858
[TBL] [Abstract] [Full Text] [Related]
4. Combining CSPG4-car and CD20-CCR for treatment of metastatic melanoma.
Teppert K; Winter N; Herbel V; Brandes C; Lennartz S; Engert F; Kaiser A; Schaser T; Lock D
Front Immunol; 2023; 14():1178060. PubMed ID: 37901209
[TBL] [Abstract] [Full Text] [Related]
5. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract] [Full Text] [Related]
6. Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.
Zhang HY; Yu HY; Zhao GX; Jiang XZ; Gao G; Wei BJ
Front Endocrinol (Lausanne); 2023; 14():1273634. PubMed ID: 37867521
[TBL] [Abstract] [Full Text] [Related]
7. B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vγ9Vδ2 T cells in glioblastoma.
Wang Y; Ji N; Zhang Y; Chu J; Pan C; Zhang P; Ma W; Zhang X; Xi JJ; Chen M; Zhang Y; Zhang L; Sun T
J Transl Med; 2023 Sep; 21(1):672. PubMed ID: 37770968
[TBL] [Abstract] [Full Text] [Related]
8. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
[TBL] [Abstract] [Full Text] [Related]
9. Chimeric Antigen Receptor T cells in Glioblastoma-Current Concepts and Promising Future.
Kringel R; Lamszus K; Mohme M
Cells; 2023 Jul; 12(13):. PubMed ID: 37443804
[TBL] [Abstract] [Full Text] [Related]
10. Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma.
Zhao B; Wu J; Li H; Wang Y; Wang Y; Xing H; Wang Y; Ma W
Cell Commun Signal; 2023 Apr; 21(1):74. PubMed ID: 37046332
[TBL] [Abstract] [Full Text] [Related]
11. IL-18-secreting car T cells targeting DLL3 are highly effective in small cell lung cancer models.
Jaspers JE; Khan JF; Godfrey WD; Lopez AV; Ciampricotti M; Rudin CM; Brentjens RJ
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36951942
[TBL] [Abstract] [Full Text] [Related]
12. Immune checkpoint inhibitors and Chimeric Antigen Receptor (car)-T cell therapy: Potential treatment options against Testicular germ cell tumors.
Schepisi G; Gianni C; Cursano MC; Gallà V; Menna C; Casadei C; Bleve S; Lolli C; Martinelli G; Rosti G; De Giorgi U
Front Immunol; 2023; 14():1118610. PubMed ID: 36860862
[TBL] [Abstract] [Full Text] [Related]
13. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract] [Full Text] [Related]
14. Immunotherapy for Pediatric Brain and Spine tumors: Current State and Future Directions.
Estevez-Ordonez D; Gary SE; Atchley TJ; Maleknia PD; George JA; Laskay NMB; Gross EG; Devulapalli RK; Johnston JM
Pediatr Neurosurg; 2023; 58(5):313-336. PubMed ID: 36549282
[TBL] [Abstract] [Full Text] [Related]
15. Glioma Stem cells: Novel Data Obtained by Single-cell Sequencing.
Gisina A; Kholodenko I; Kim Y; Abakumov M; Lupatov A; Yarygin K
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430704
[TBL] [Abstract] [Full Text] [Related]
16. [Melanoma-associated macrophages-from molecular signals to therapeutic application].
Chatziioannou E; Aydin SA; Forchhammer S; Sinnberg T; Eigentler T
Dermatologie (Heidelb); 2022 Dec; 73(12):915-928. PubMed ID: 36394590
[TBL] [Abstract] [Full Text] [Related]
17. Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
Front Immunol; 2022; 13():944452. PubMed ID: 36311781
[TBL] [Abstract] [Full Text] [Related]
18. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
Wang C; Yu M; Zhang W
Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
[TBL] [Abstract] [Full Text] [Related]
19. Clinical utility of car T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes.
Chatterjee A; Asija S; Yadav S; Purwar R; Goda JS
Int Rev Immunol; 2022; 41(6):606-624. PubMed ID: 36191126
[TBL] [Abstract] [Full Text] [Related]
20. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract] [Full Text] [Related]
[Next]
